PAQR3 plays a suppressive role in laryngeal squamous cell carcinoma

Wu, Qiang; Zhuang, Kun; Li, Huijun

doi:10.1007/s13277-015-3770-y

Cited by 19 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The progestin and adipoQ receptor family, named as PAQR, is a highly conserved protein family that is composed of 11 members, PAQR1 to PAQR11 [ 5 ]. PAQR3 was recently discovered as a new member of tumor suppressor that is deregulated in different types of human cancer including colon cancer, gastric cancer, bladder cancer, liver cancer, osteosarcoma, breast cancer, and laryngeal squamous cell carcinoma [ 6 – 12 ]. PAQR3, also named as RKTG for Raf kinase trapping to Golgi, is a seven-transmembrane protein that is a type III membrane protein specifically localized in the Golgi apparatus in mammalian cells [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

PAQR3 suppresses the proliferation, migration and tumorigenicity of human prostate cancer cells

et al. 2016

View full text Add to dashboard Cite

As a newly discovered tumor suppressor, the potential function of PAQR3 in human prostate cancer has not been demonstrated. In this study, we report that PAQR3 is able to inhibit the growth and migration of human prostate cancer cells both in vitro and in vivo. Overexpression of PAQR3 inhibits the proliferation of PC3 and DU145 cells by both MTT and colony formation assays. Consistently, knockdown of PAQR3 enhances the proliferation of these cells. In wound-healing and transwell assays, overexpression of PAQR3 reduces the migration of PC3 and DU145 cells, while PAQR3 knockdown increases it. In a tumor xenograft model, overexpression of PAQR3 suppresses tumor growth of PC3 cells in vivo, while PAQR3 knockdown promotes the tumor growth. PAQR3 is also able to inhibit serum-induced phosphorylation of AKT and ERK in both PC3 and DU145 cells. In addition, PAQR3 suppresses the expression of epithelial-mesenchymal transition (EMT) markers in PC3 cells. Collectively, these data indicate that PAQR3 has a tumor suppressive activity in human prostate cancer cells and may stand out as a potential therapeutic target for prostate cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

PAQR3 suppresses the proliferation, migration and tumorigenicity of human prostate cancer cells

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Moreover, increased PAQR3 expression inhibited the growth of ECA-109 cell xenograft tumors ( Zhou et al, 2017 ; Bai et al, 2017 , 2018 ). Compared with adjacent tissues, the expression of PAQR3 in laryngeal squamous cell carcinoma (LSCC) tissues was significantly downregulated, and overexpression of PAQR3 inhibited the proliferation and invasion of LSCC cells ( Wu et al, 2016 ). In osteosarcoma, the expression of PAQR3 was decreased and was associated with metastasis in patients.…”

Section: Discussionmentioning

confidence: 99%

PAQR3 Inhibits Non-small Cell Lung Cancer Growth by Regulating the NF-κB/p53/Bax Axis

Guo

Fang

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Background The expression of progestin and adipoQ receptor 3 (PAQR3) is generally downregulated in multiple tumors, which is associated with tumor progression and poor prognosis. Methods The clinical value of PAQR3 was analyzed using various databases and in 60 patients with non-small cell lung cancer (NSCLC). In addition, cell counting kit-8 (CCK-8), colony formation, and flow cytometry assays were used to evaluate the effect of PAQR3 on the growth of NSCLC cells in vitro . Gene set enrichment analysis (GSEA) was performed to investigate the possible mechanism through which PAQR3 is involved in the progression of lung cancer. Furthermore, western blotting was employed to verify the relevant mechanism. Results The expression of PAQR3 was decreased in 60 NSCLC patients and was related to the histological subtype, lymph node metastasis, tumor size, and diagnosis of NSCLC. Patients with lung adenocarcinoma with increased PAQR3 expression tended to have a better prognosis. Besides, PAQR3 inhibited proliferation, clone formation, and cycle transition in NSCLC cells, but induced apoptosis. The results of GSEA showed that PAQR3 regulated the progression of lung cancer by affecting cell cycle, DNA replication, and the p53 signaling pathway. We confirmed that PAQR3 overexpression inhibited the expression of NF-κB, while it increased the expression of p53, phospho-p53, and Bax. On the contrary, PAQR3 inhibition played an opposite role in these proteins. Conclusion PAQR3 inhibited the growth of NSCLC cells through the NF-κB/P53/Bax signaling pathway and might be a new target for diagnosis and treatment.

show abstract

“…PAQR3 overexpression decreased the phosphorylation of ERK1/2 in ESCC cells, without affecting the activation of Akt ( 21 ). PAQR3 has demonstrated the ability to interfere with multiple aspects of tumor biology, including proliferation, migration, invasion, and EMT ( 22 , 23 ). In the present study, it was revealed that the overexpression of PAQR3 suppressed EMT features as demonstrated by the marked increase in the epithelial marker E-cadherin.…”

Section: Discussionmentioning

confidence: 99%

Suppressor PAQR3 associated with the clinical significance and prognosis in esophageal squamous cell carcinoma

et al. 2018

View full text Add to dashboard Cite

Progestin and adipoQ receptor family member 3 (PAQR3) is a novel tumor suppressor; however, its function in esophageal cancer is not well understood. The present study explored the association between PAQR3, and the survival and clinical phenotype in patients with esophageal squamous cell carcinoma (ESCC). The expression of PAQR3 in 80 cases of ESCC and its corresponding adjacent tissues was detected by reverse transcription-quantitative polymerase chain reaction. The results demonstrated that PAQR3 expression in cancer tissues was significantly lower compared with that in adjacent tissues. Clinicopathological analysis indicated that PAQR3 expression was significantly correlated with ethnicity (P=0.032), tumor length (P=0.019), lymph node metastasis (P=0.011) and local recurrence (P=0.009). Notably, the Kaplan-Meier survival curve demonstrated that a decrease in PAQR3 expression was associated with poor prognosis in patients with ESCC. Multivariate analysis indicated that PAQR3 expression was an independent prognostic indicator for patients with ESCC. PAQR3 may serve an important role in the progress of ESCC and become a potential candidate for ESCC targeted therapy.

show abstract

PAQR3 plays a suppressive role in laryngeal squamous cell carcinoma

Cited by 19 publications

References 20 publications

PAQR3 suppresses the proliferation, migration and tumorigenicity of human prostate cancer cells

PAQR3 suppresses the proliferation, migration and tumorigenicity of human prostate cancer cells

PAQR3 Inhibits Non-small Cell Lung Cancer Growth by Regulating the NF-κB/p53/Bax Axis

Suppressor PAQR3 associated with the clinical significance and prognosis in esophageal squamous cell carcinoma

Contact Info

Product

Resources

About